A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identifiedAT-108 combines the advantages of an off-the-she ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

The capacity of an organism to regenerate depends on cell dedifferentiation followed by proliferation. Mammals, in general, have limited regenerative capacity. Now, a team of researchers at the Salk ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The discovery demonstrates a ...